<DOC>
	<DOCNO>NCT02145988</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , double-dummy , control study DLBS1033 improvement ankle-brachial index diabetic patient peripheral arterial disease ( PAD ) . It hypothesize addition DLBS1033 top aspirin treatment augment significantly rest ABI diabetes patient PAD comparison aspirin alone .</brief_summary>
	<brief_title>DLBS1033 Treatment Diabetic With Peripheral Arterial Disease</brief_title>
	<detailed_description>Subjects study screen consecutively eligible subject randomize receive aspirin tablet 80 mg daily either investigational drug ( DLBS1033 tablet 490 mg three time daily ) placebo , 12 week . Diabetic subject therapy aspirin directly start study treatment . For currently therapy aspirin , run-in period receive ( switch ) aspirin treatment , two week . After , receive study medication . Clinical laboratory examination evaluate investigational drug 's efficacy safety perform baseline interval six week twelve week-course therapy .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Signed informed consent trial related activity . Male female subject 40 65 year age . Diagnosis diabetes mellitus define HbA1c level ≥ 6.5 % ( newly diagnose diabetes ) base medical history . Presence peripheral arterial disease rest anklebrachial index ( ABI ) 0.410.90 inclusive Females childbearing potential : pregnancy , breastfeeding , intention become pregnant . Recent stroke attack , myocardial infarction/unstable angina/acute coronary syndrome , coronary artery bypass surgery ( CABG ) percutaneous transluminal coronary angioplasty ( PTCA ) /stent within 3 ( three ) month prior screen . Impaired liver function : serum ALT &gt; 2.5 time upper limit normal . Impaired renal function : serum creatinine ≥ 1.5 time upper limit normal . Concomitant use antithrombosis drug antiplatelets study medication . Subjects concurrent herbal ( alternative ) medicine food supplement Subjects disease state , include chronic acute systemic infection , uncontrolled illness chronic disease , judge investigator , could interfere trial participation trial evaluation . Subjects high risk bleeding : Subjects prior experience DLBS1033 oral lumbrokinase product . Subjects know suspect allergy study medication use study , include lumbrokinase product . Subjects know suspected allergy resistant aspirin .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>DLBS1033</keyword>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>Ankle-brachial index</keyword>
</DOC>